64 results about "Therapeutic strategy" patented technology

This invention belongs to the field of biomedical technology, specifically relating to the discovery and application of biomarkers for predicting the efficacy of immunotherapy in nasopharyngeal carcinoma. This invention provides a reliable combination of 10-gene TLS biomarkers that can effectively predict the pathological TLS status in nasopharyngeal carcinoma tissue. This 10-gene TLS biomarker combination exhibits stable and significant prognostic predictive value: regardless of standard treatment or immunotherapy, a high TLS score can effectively identify patients with better survival outcomes (such as FFS, OS, and DMFS), providing important evidence for individualized risk assessment and treatment strategy selection.

This invention provides a genetically engineered biomimetic microsphere for hydration remodeling, its preparation method, and its application, belonging to the field of biomedical technology. This invention develops an injectable composite system, GBA / SRGN@HADA@GelMA, which possesses the ability to regulate hydration and intervene in genes through interface biomimetic design and multi-level functional integration. It uses HADA as a moisturizing outer layer, provides mechanical support through GelMA microspheres, and achieves targeted delivery of SRGN siRNA through G5-GBA loading, thereby achieving synergistic regulation of the degenerative nucleus pulposus microenvironment. GBA / SRGN@HADA@GelMA reduces the expression of inflammatory factors and matrix degradation genes, and significantly promotes the accumulation of HA and lubricating proteins. This enhances the water retention capacity and interfacial lubrication of the nucleus pulposus, thereby improving compressive elasticity and energy absorption capacity. This invention is the first to combine continuous water regulation, lubrication, mechanical buffering, and extracellular matrix homeostasis regulation to synergistically delay intervertebral disc degeneration, providing an excellent treatment strategy for degenerative intervertebral disc diseases.

This application relates to the field of biomedical technology and discloses the application of juniperol or its derivatives in the preparation of drugs that inhibit Drp1-mediated excessive mitochondrial division. This application verifies through in vitro and in vivo experiments that juniperol can inhibit phosphorylation at the Ser616 site of Drp1 and Drp1 mitochondrial translocation, thereby inhibiting Drp1-mediated excessive mitochondrial division. This demonstrates a good therapeutic effect on mitochondrial excessive division-related diseases such as inflammatory bowel disease, providing a new therapeutic strategy for the treatment of these diseases and possessing significant clinical implications.

This invention discloses a pharmaceutical composition containing the natural products osthol and berberine, exhibiting synergistic antibacterial and antifungal effects. The effectiveness of osthol in synergistically enhancing the antibacterial activity of berberine was demonstrated through checkerboard minimum inhibitory concentration (MIC) tests, antifungal activity experiments, and in vitro bacterial growth curves. This invention provides a novel application of the combined use of osthol and berberine in antibacterial and antifungal treatments. This composition belongs to the category of traditional Chinese medicine compound preparations, offering a new treatment strategy for the clinical treatment of bacterial and fungal infectious diseases.

The application provides an application of a traditional Chinese medicine preparation in preparation of a drug for treating dysmenorrhea, and an active ingredient of the traditional Chinese medicine preparation is prepared from liquorice, asarum, cassia twig, angelica, white peony root, common sage and chuanxiong. The traditional Chinese medicine preparation provided by the application fuses multi-dimensional treatment strategies of warming meridians, nourishing blood, regulating qi and dredging collaterals, and can cover different TCM syndrome types such as cold coagulation and blood stasis, qi stagnation and blood stasis and qi and blood deficiency. Pharmacological experiments show that for dysmenorrhea rats of the cold coagulation and blood stasis type, the traditional Chinese medicine preparation of the application can reduce the sensitivity of the uterus caused by benzoic acid estradiol and inhibit the writhing reaction of the rats caused by oxytocin, which indicates that the traditional Chinese medicine preparation of the application has the effect of treating dysmenorrhea.

The application discloses a diabetic nephropathy pathological model based on human renal tubular epithelial cell organoids and a construction method and application thereof, and belongs to the field of biomedical technology. The construction method comprises the following steps: jointly inducing the renal tubular epithelial cell organoids in a culture medium containing glucose, advanced glycation end products and tumor necrosis factor alpha to prepare the diabetic nephropathy pathological model. The diabetic nephropathy pathological model is constructed by joint induction, the model shows the core pathological phenotypes of diabetic nephropathy, including down-regulation of renal tubular epithelial cell marker expression, up-regulation of fibrosis marker expression, thickening of the basement membrane and abnormal albumin uptake function, the construction method is simple and standardized, the construction period is short, the model has good repeatability and stability, the model has wide application value in high-throughput screening of traditional Chinese medicine monomers or compound medicines with kidney protection, and provides a new platform for mechanism research and treatment strategy development of diabetic nephropathy.

This invention discloses the application of substances that inhibit Trx1 nitration in the preparation of drugs for treating Trx1 nitration-related diseases. This invention reveals for the first time that nitration modification of tyrosine residue 49 (Y49) of the Trx1 protein is a key pathological step in diseases such as ischemic stroke and myocardial ischemia-reperfusion injury. Inhibiting nitration at this site can effectively restore Trx1 reductase activity, enhance the binding of Trx1 to ASK1, and block the downstream ASK1-p38 / JNK apoptosis signaling pathway, thereby exerting a therapeutic effect. This invention provides a novel treatment strategy for Trx1 nitration-related diseases.

This invention belongs to the field of molecular biology technology, specifically involving tRF5-22-SeCTCA-1, tRF5-22-SeCTCA-1 detection reagents, kits, and their applications. This invention discovers and verifies that tRF5-22-SeCTCA-1 plays a key regulatory role in the process of 5-fluorouracil (5-FU) chemotherapy resistance in colorectal cancer, filling a gap in the research of tRNA-derived fragments (tRFs) in colorectal cancer chemotherapy resistance. It is the first tRF molecule reported to be associated with 5-FU chemotherapy resistance in colorectal cancer, providing a novel molecular target and research direction for predicting chemotherapy resistance in colorectal cancer. This invention also provides a therapeutic strategy targeting tRF5-22-SeCTCA-1 and establishes α-ketoglutarate as an independent reversal agent, providing multi-dimensional technical solutions for the precision diagnosis and treatment of colorectal cancer and the reversal of chemotherapy resistance.

This invention discloses a ROS-responsive endothelial cell-targeting prodrug compound, its preparation method, and its applications, relating to the fields of biomedicine and medicinal chemistry. The ROS-responsive endothelial cell-targeting prodrug compound is VHP-TK-Tro. The preparation method of this prodrug compound includes the following steps: S1, reacting the ketothiol diamine derivative TK-NH2 with triphosgene to obtain an activated intermediate; S2, reacting the activated intermediate with Trolox to obtain TK-Trolox; S3, reacting TK-Trolox with the targeting peptide VHPKQHRGDWC. This prodrug compound is used in the preparation of drugs for the treatment or prevention of oxidative stress-mediated inflammatory diseases. This prodrug compound achieves active targeted drug delivery. The preparation method provided by this invention is simple, mild, and produces a high-purity product, making it easy to scale up production. This prodrug compound is expected to provide a novel, highly effective, and low-toxicity therapeutic strategy for related diseases.

This invention provides the application of chlorogenic acid in the preparation of drugs for treating intranuclear inclusion body disease (NIID), belonging to the field of pharmaceutical technology. This invention utilizes widely available sources with abundant safety data. Compared to novel chemical entities, chlorogenic acid, with its lower development risk, is used as a raw material. It has been found that chlorogenic acid can enhance the interaction between polyG protein and the E3 ubiquitin ligase TRIM21, forming a stable TRIM21-chlorogenic acid-polyG ternary complex. This promotes polyG ubiquitination and proteasome-dependent degradation, thereby reducing intracellular inclusion body burden and alleviating NIID from its pathological root cause. This provides a safe, effective, and highly specific new targeted therapeutic strategy for NIID.

This invention provides a method for preparing and applying a nanosystem for regulating the osteogenic microenvironment. The nanosystem comprises catalase, lactate oxidase, and a strontium-containing mineralized nanolayer. Experiments demonstrate that this nanosystem can effectively treat bone aging-related diseases, and that catalase and lactate oxidase have a synergistic effect. This invention provides a novel treatment strategy for bone aging-related diseases and has broad prospects for clinical translation.

This invention relates to the field of biomedical materials technology and provides an application of obeticholic acid-exosome nanoparticles in the treatment of hepatic ischemia-reperfusion injury. The obeticholic acid-exosome nanoparticles are prepared by combining exosomes and obeticholic acid using an ultrasonic method, wherein the exosomes are derived from human bone marrow mesenchymal stem cells. The method for preparing the obeticholic acid-exosome nanoparticles is simple and easy to mass-produce. By utilizing exosomes derived from mesenchymal stem cells, the obeticholic acid-exosome nanoparticles improve the drug's targeting in vivo and prolong its circulation time, achieving targeted delivery of obeticholic acid to the liver, thus providing a new targeted therapeutic strategy for hepatic ischemia-reperfusion injury.

This invention discloses the application of disodium 4,4'-diisothiocyanate-2,2'-stilbene sulfonate in the preparation of drugs for the prevention, delay, and / or treatment of blue light-induced retinal damage. It belongs to the field of biomedical technology. This invention demonstrates for the first time that sodium DIDS can effectively protect photoreceptor cells from blue light damage: at the cellular level, sodium DIDS can restore mitochondrial membrane potential, increase ATP levels, reduce reactive oxygen species accumulation, and inhibit mitochondrial-dependent apoptosis; at the animal level, intravitreal injection of sodium DIDS can improve vision in mice exposed to blue light, restore the amplitude of a-waves and / or b-waves in electroretinograms, and protect the outer segment length and outer nuclear layer thickness of cone cells. Sodium DIDS provides a novel therapeutic strategy for blue light-induced retinal photodamage through multi-target synergistic protection of mitochondrial function.

The application discloses application of barbatusoside B in resisting liver and brain aging, and belongs to the field of medicinal chemistry. Experimental data of the application show that the barbatusoside B can significantly reduce tissue damage and inflammatory response of the aging liver, improve liver function, and prolong healthy life, and provides a new treatment strategy for resisting liver aging and related diseases; meanwhile, the barbatusoside B can also significantly improve oxidative damage and neural inflammation of the aging brain, protect neuron function, and enhance cognitive ability, and provides a new treatment strategy for resisting brain aging and related neurodegenerative diseases.

This invention relates to a therapeutic target for metabolic dysfunction-related fatty liver disease (MAFLD) and hepatitis, and its application, belonging to the field of biomedical technology. This invention is the first to discover that the expression level of DPF2 in Lgr5-positive hepatocytes can specifically determine the severity of MAFLD and MASH. Based on this finding, this invention significantly improves the pathological structure of MASH by overexpressing DPF2 in Lgr5-positive hepatocytes, demonstrating that targeting Lgr5-positive hepatocytes in the liver can be a therapeutic strategy for metabolic-related fatty liver disease. This invention provides a novel therapeutic target for the treatment of MAFLD / MASH, which has good specificity and broad application prospects.

This invention belongs to the field of biomedical technology, specifically relating to compounds for treating KRAS-mutant tumors and their uses. This invention provides compound 666-15, which provides dual inhibition of cytoplasmic-mitochondrial NAD5. + Transport (via targeting SLC25A51) and succinate dehydrogenase (SDH / complex II), while simultaneously disrupting mitochondrial NAD. + Transport and respiratory chain NAD + A novel therapeutic strategy to target KRAS-mutant tumors by utilizing regenerative functions.

This invention provides the application of exercise-induced sweat extract from healthy individuals in the preparation of a topical medication for diabetic foot ulcers, belonging to the field of biomedicine. Addressing the problems of high cost and limited efficacy of existing treatments, this invention creatively proposes to collect, wash, centrifuge, and filter sweat from healthy individuals induced by specific moderate-intensity aerobic exercise to prepare a sterile extract, which can be used as an active ingredient for topical treatment of diabetic foot ulcers. This sweat extract is rich in various bioactive components. In vitro transcriptomic analysis shows that it can reverse the abnormal gene expression profile associated with diabetic foot ulcers. In vivo animal experiments have confirmed that its topical application can significantly accelerate the healing of diabetic wounds through multi-target synergistic effects of anti-inflammation, angiogenesis, epithelialization, and collagen deposition, with effects comparable to recombinant growth factors. This invention provides a novel treatment strategy that is natural, safe, low-cost, and highly effective, with broad clinical application prospects.

The composition and methods of treatment disclosed or contemplated herein include compositions and methods of treatment for liver-related diseases. The overall treatment strategy would involve the identification of a target protein or receptor within the liver that is responsible for ongoing liver injury. The strain of orally administered Salmonella Typhimurium that colonizes the liver would be engineered to secrete a particular protein or nanobody that would stop and / or reverse the progressive hepatic disease

This invention belongs to the field of small molecule pharmaceutical compounds and relates to the application of trimetazidine in the preparation of drugs for treating glycogen storage diseases. This invention provides a novel treatment strategy for glycogen storage diseases, discovering that the small molecule compound trimetazidine can reduce the load on lysosomal pathways, further reducing cellular glycogen accumulation, thus achieving a therapeutic effect on glycogen storage diseases. In animal experiments, observations of skeletal muscle movement in mice confirmed that trimetazidine significantly enhances muscle function and strength in mice with glycogen storage diseases. Therefore, trimetazidine can be used clinically for the prevention or treatment of glycogen storage diseases, and possesses the advantages of small molecular weight, oral administration, and low cost for industrialization.

This invention discloses a bivalent ligand molecule targeting EGFR and its applications, belonging to the field of drug development technology. Its general structural formula is: [Formula omitted for brevity], where L is a linking group, and M1 and M2 are EGFR protein ligands. This invention forms a bivalent EGFR ligand molecule by covalently linking two EGFR ligands through a linking group. This bivalent ligand molecule can induce additional protein-protein interactions between EGFR monomers, which greatly enhances the binding strength and stability of the drug to EGFR, thereby overcoming the drug resistance problem of traditional EGFR inhibitors and providing a new treatment strategy for cancer patients carrying EGFR mutations and other patients with other diseases.

The application provides a gold nano drug delivery system with pH / NIR-II dual response characteristics and a preparation method thereof, and is prepared by sequentially preparing a gold nanocage (AuNC), a mesoporous silica coated AuNC (AuNC@mSiO2), an amino modified AuNC@mSiO2 (AuNC@mSiO2-NH2), a drug or dye loaded AuNC@mSiO2-NH2 (AuNC@mSiO2-NH2 intersection drug / dye), a PAA coated AuNC@mSiO2-NH2 intersection drug / dye (AuNC@mSiO2@PAA), and finally modifying with PEG and iRGD to obtain the gold nano drug delivery system ASPPR with a core-shell-membrane sandwich structure; the gold nano drug delivery system can realize precise cooperation of photothermal effect and mTOR inhibition in time and space, targets tumor to deliver an mTOR inhibitor first, restores antigen presentation, and then carries out photothermal therapy, so that better treatment conditions are provided for the photothermal therapy, and a combined treatment strategy is optimized.

The application provides use of an inhibitor targeting IL-11 or an IL-11 receptor in preparation of a drug for delaying ovarian aging, and first discloses and proves that an inflammatory factor interleukin-11 (IL-11) is a core target point for driving ovarian aging and an increase in ovarian matrix stiffness and fibrosis under pathological conditions such as chemotherapy damage and polycystic ovary syndrome, and the interleukin-11 promotes excessive secretion of collagen by activating an IL-11RA / ERK signal axis in ovarian fibroblasts. Based on this, the application provides a new use of an inhibitor (such as specific siRNA and a neutralizing antibody) targeting IL-11 or the receptor thereof in preparation of a related therapeutic drug. In particular, a liposome nanoparticle loaded with IL-11 siRNA can effectively reduce ovarian stiffness, reduce fibrosis, significantly improve follicle reserve, hormone level and fertility, and successfully reverse the ovarian aging phenotype in old mice, rats and various disease models. The application provides a new effective target point, a treatment strategy and a product prototype with a transformation potential for intervention on ovarian aging and related diseases.

This invention discloses the use of arginine polyesteramide in the preparation of drugs for treating dry age-related macular degeneration (AMD). This invention is the first to discover that arginine polyesteramide 2A6S can be used to prevent and treat dry age-related macular degeneration (AMD). Specifically, 2A6S can effectively restore ERG amplitude in patients with dry AMD, reduce fundus pathological damage and maintain the integrity of the retinopathy of prematurity (RPE), and reduce the expression of inflammatory factors by inhibiting the NF-κB pathway. Its efficacy is superior to existing complement C3 inhibitory peptides and NF-κB signaling pathway inhibitors, and it has potential clinical application value for dry AMD, contributing to the expansion of treatment strategies for dry AMD.

This invention discloses the application of apolipoprotein M in the preparation of a medicament for treating heart failure with preserved ejection fraction (HFpEF). The medicament comprises apolipoprotein M and a medically acceptable carrier or excipient. Animal experiments have shown that liver-specific overexpression of ApoM improves diastolic dysfunction, myocardial hypertrophy, and myocardial fibrosis in HFpEF mice, while liver-specific knockdown of ApoM exacerbates this pathological process. This provides a novel treatment strategy for HFpEF and also offers a theoretical basis for ApoM as a biomarker for HFpEF.

The present application relates to the field of biological medicine, in particular to a mutant protein related to Notch signal pathway and use thereof. The mutant protein provided by the present application is a mutant Notch1 protein, a mutant DLL4 protein or a mutant JAG1 protein. The mutant protein related to Notch signal pathway provided by the present application: the mutant Notch1 protein has strong activation signal after binding with its ligands DLL4 and JAG1, and is used for regulating the disorder of Notch signal pathway, and can provide a basis for the occurrence mechanism research and development of treatment strategies of developmental disorders, cancers and other diseases.

This invention belongs to the field of liver disease research and biomedicine, specifically relating to the application of reagents targeting and inhibiting OXCT1 in combination with BHB or pharmaceutically acceptable salts thereof in the preparation of anti-HCC drugs. The reagents inhibiting OXCT1 include: siRNA, shRNA, antisense nucleic acid, and gene editing reagents that reduce OXCT1 expression; and small molecule inhibitors, peptides, antibodies, or fusion proteins that inhibit OXCT1 enzyme activity. This invention proposes a novel therapeutic strategy of targeting and inhibiting OXCT1 in combination with BHB. Studies have shown that targeting and inhibiting OXCT1 can block the pro-cancer metabolic pathway of BHB, reducing the effective concentration of BHB for its anti-cancer effect, enabling it to achieve significant anti-cancer effects at clinically tolerable concentrations and exert a synergistic anti-tumor effect. This invention solves the problem of limited clinical application of high-concentration BHB and provides a new combination therapy regimen with clinical translational potential for hepatocellular carcinoma.

The application discloses genetically engineered ferritin against alpha synuclein, a preparation method and application thereof, and belongs to the technical field of biological medicine and protein engineering. The genetically engineered ferritin is constructed by fusing and expressing NACore polypeptide and human heavy chain ferritin through gene recombination technology, and has alpha synuclein aggregation inhibition activity. The genetically engineered ferritin can specifically combine with the NAC region of alpha synuclein, significantly inhibits the misfolding and aggregation of alpha synuclein, and provides a new drug raw material and treatment strategy for the treatment of Parkinson's disease and other alpha synuclein related neurodegenerative diseases. The genetically engineered ferritin prepared by the application has uniform particle size distribution and stable physicochemical properties. Molecular simulation verifies that the genetically engineered ferritin can efficiently combine with the NAC region of alpha synuclein. ThT fluorescence detection and CCK-8 experiments prove that the genetically engineered ferritin can inhibit the aggregation and fibrosis of alpha synuclein, and lays a solid foundation for the clinical treatment of related diseases.

This invention discloses the application of NLRX1 protein inhibitors in the preparation of products with protective effects against pulmonary fibrosis, belonging to the field of biomedical technology. This invention, through the use of an NLRX1 gene knockout mouse model and siRNA silencing technology, demonstrates that inhibiting NLRX1 can significantly alleviate bleomycin-induced pulmonary fibrosis pathological damage. Its protective mechanisms include promoting the proliferation of type II alveolar epithelial cells, inhibiting their damage and apoptosis, and reducing myofibroblast infiltration and extracellular matrix deposition. Based on this, this invention provides for the first time a therapeutic strategy targeting the inhibition of the NLRX1 protein. Related products include recombinant vectors containing RNA molecules encoding NLRX1 expression inhibitors or other drugs capable of inhibiting NLRX1 expression. This invention provides new targets and drug development directions for the treatment of fibrotic diseases, especially pulmonary fibrosis.

This invention discloses a combination formulation of a BRD7 stabilizer and a HER2-targeting drug, and its application, belonging to the field of pharmaceutical molecular biology. This invention is the first to discover that BRD7 can upregulate HER2 protein stability in triple-negative breast cancer, promoting the transformation of triple-negative breast cancer cells to HER2-positive cells, thereby increasing the sensitivity of triple-negative breast cancer cells to HER2-targeting antibody drugs. Further research demonstrates that BRD7 increases HER2 protein stability by inhibiting HER2 protein degradation mediated by the autophagy-lysosomal pathway. Therefore, the combination of a BRD7 stabilizer drug and a HER2-targeting monoclonal antibody drug exhibits significant anti-tumor effects. This invention provides a potential treatment strategy for the clinical treatment of triple-negative breast cancer and has broad application prospects.